Pyxis Oncology (NASDAQ:PYXS) Releases Earnings Results, Hits Expectations

Pyxis Oncology (NASDAQ:PYXS) issued its quarterly earnings results on Tuesday. The company reported ($0.32) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.32), Zacks reports.

Pyxis Oncology Trading Up 4.5 %

PYXS stock opened at $1.16 on Tuesday. The stock has a market capitalization of $68.98 million, a PE ratio of -1.13 and a beta of 1.11. The stock’s 50 day simple moving average is $1.37 and its 200 day simple moving average is $2.42. Pyxis Oncology has a 12-month low of $0.99 and a 12-month high of $6.18.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on PYXS shares. William Blair lowered shares of Pyxis Oncology from an “outperform” rating to a “market perform” rating in a report on Thursday, November 21st. Royal Bank of Canada reissued an “outperform” rating and issued a $8.00 target price (down from $10.00) on shares of Pyxis Oncology in a report on Friday, December 20th. Finally, HC Wainwright restated a “buy” rating and set a $5.00 price target (down from $7.00) on shares of Pyxis Oncology in a report on Friday, December 20th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, Pyxis Oncology currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.20.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Pyxis Oncology stock. Bank of America Corp DE boosted its holdings in Pyxis Oncology, Inc. (NASDAQ:PYXS) by 20.3% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 53,745 shares of the company’s stock after buying an additional 9,062 shares during the quarter. Bank of America Corp DE owned 0.09% of Pyxis Oncology worth $84,000 at the end of the most recent quarter. Institutional investors own 39.09% of the company’s stock.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.